Joint venture to benefit presbyopia patients

Article

Technolas Perfect Vision is the new company name for the joint venture between Bausch & Lomb and 20/10 Perfect Vision AG that will focus on laser vision correction.

Technolas Perfect Vision is the new company name for the joint venture between Bausch & Lomb and 20/10 Perfect Vision AG that will focus on laser vision correction.

The business will initially concentrate on treatments for presbyopia and aims to provide clinicians with advanced excimer and femtosecond laser technology. One of its new procedures is INTRACOR, an intrastromal treatment, which carries the CE mark for treatment of presbyopic hypreopes.

Dr Kristian Hohla, Technolas's new CEO sees this as potentially huge: "These are breakthrough technologies, transforming the lifestyle of presbyopia sufferers and providing clinicians with a wonderful opportunity to attract a stream of new patients to their refractive practices."

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.